The myoepithelial cell: its role in normal mammary glands and breast cancer by Sopel, M.
Folia Morphol.
 Vol. 69, No. 1, pp. 1–14
Copyright © 2010 Via Medica
ISSN 0015–5659
www.fm.viamedica.pl
R E V I E W   A R T I C L E
1
Address for correspondence: Dr. M. Sopel, Wrocław Medical University, Department of Histology and Embryology, Chałubińskiego 6a,
50–368 Wrocław, Poland, tel: +48 605 26 46 40, e-mail: mirek.sopel@gmail.com
The myoepithelial cell: its role in normal
mammary glands and breast cancer
M. Sopel
Department of Histology and Embryology, Wrocław Medical University, Wrocław, Poland
[Received 19 November 2009; Accepted 26 December 2009]
Mammary gland epithelium is composed of an inner layer of secretory cells (lu-
minal) and an outer layer of myoepithelial cells (MEC) bordering the basal lamina
which separates the epithelial layer from the extracellular matrix. Mature MECs
morphologically resemble smooth muscle cells; however, they exhibit features
typical for epithelial cells, such as the presence of specific cytokeratin filaments.
During lactation, secretory cells synthesize milk components, which are collected
in alveoli and duct lumen, and transported to the nipple as a result of MEC
contraction. Although the induction of MEC contraction results from oxytocin
action, also other, still unknown auto/paracrine mechanisms participate in the
regulation of this process. As well as milk ejection, MECs are involved in mamma-
ry gland morphogenesis in all developmental stages, modulating proliferation
and differentiation of luminal cells. They take part in the formation of extracellu-
lar matrix, synthesizing its components and secreting proteinases and their inhi-
bitors. In addition, MECs are regarded as natural cancer suppressors, stabilizing
the normal structure of the mammary gland, they secrete suppressor proteins
(e.g. maspin) limiting cancer growth, invasiveness, and neoangiogenesis. The
majority of malignant breast cancers are derived from luminal cells, whereas
neoplasms of MEC origin are the most seldom and usually benign form of breast
tumours. MECs are markedly resistant to malignant transformation and they are
able to suppress the transformation of neigh boring luminal cells. Therefore,
a deeper insight into the role of MECs in the physiology and pathology of mam-
mary glands would allow a better understanding of cancerogenesis mechanisms
and possible application of specific MEC markers in the diagnosis and therapy of
breast cancer. (Folia Morphol 2010; 69, 1: 1–14)
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LOCALIZATION AND STRUCTURE
OF MAMMARY GLAND
MYOEPITHELIAL CELLS
Normal mammary glands are composed of
a branched system of excretory ducts and secretory
alveoli organized in lobules separated from each
other by stroma. The epithelium of ducts and secre-
tory alveoli consists of two layers of cells: a layer of
luminal cells, which is responsible for the synthesis
and secretion of milk components, and a layer of
myoepithelial cells (MEC). The key role of MECs is
their participation in the process of milk ejection.
However, a great body of evidence has been accu-
mulated suggesting their engagement in a wide
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variety of other important physiological processes,
i.e. the regulation of mammary gland growth, de-
velopment, and differentiation, as well as the con-
trol of cancerogenesis [23].
In excretory ducts, MECs are arranged in an al-
most continuous layer, with their longer axis being
laid parallel to the ducts. In secretory units, they tend
to acquire a basket-like shape (Fig. 1). In both cas-
es, MECs are located between the basement lamina
and luminal cells, and attached to the luminal cells
by desmosomes, and by hemidesmosomes to the
basement lamina [28].
Basement lamina is mostly a product of MECs
and consists of collagen IV, fibronectin, laminin, ni-
dogen, glycosaminoglycans, and proteoglycans. It
forms a continuous layer separating myoepithelial
cells from the stroma. Receptors of basement lami-
na components, especially integrins, present in
MECs, are responsible for interactions with the ma-
trix and neighbouring cells [33].
MEC exhibit expression of proteins typical for the
contractile apparatus of smooth muscles cells, a-actin
of smooth muscles (SMA), myosin heavy chains, a-ac-
tinin, vinculin, and calponin. MEC cytoplasm is filled
with bundles of actin microfilaments and myosin fila-
ments responsible for cell contraction. Sub-membrane
dense plaques and cytoplasmic dense bodies organize
the spatial arrangement of the contractile apparatus.
In MEC processes, bundles of actin microfilaments are
concentrated on one surface of the cell bordering with
basement lamina (Figs. 2, 3).
Unlike in smooth muscle cells, intermediate fila-
ments consist mostly of cytokeratins (CK5, CK14, and
CK17) which create a net around the nucleus, ex-
tend towards the cell surface, and finally, as parallel
bundles enter the processes, reinforcing their struc-
ture. In particular, cytokeratins 5 and 14 are involved
in the maintenance of MEC cytoarchitecture, as well
as the formation of desmosomes and hemidesmo-
somes [36].
Plasma membrane forms numerous invagina-
tions (caveolae) and subsurface vesicles which are
characteristic for both myoepithelial and smooth
muscle cells (Fig. 3). The function of caveolae is
debatable; they are supposed to act as a kind of
storage for extracellular calcium ions, participate
in the process of endocytosis, or mediate the
transport of molecules between luminal cells and
the extracellular matrix. Numerous caveolae ar-
ranged in parallel rows and located between bun-
dles of microfilaments at the basal cell surface
bordering with basement lamina suggest their
Figure 1. Three-dimensional arrangement of myoepithelial cell
morphology in whole mammary gland tissue from a lactating
mouse, visualized by the fluorescent stain NBD-phallicidin, which
binds specifically to actin filaments. The cells display long, thin
processes that radiate from the cell body (¥600).
Figure 2. Transmission electron micrograph of lactating mouse
mammary epithelium. Myoepithelial cell (MEC) processes radiat-
ing from the cell body are interposed between the basal surface
of epithelial cells (EC) and the basal lamina (¥6000).
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possible participation in MEC cytoskeleton arran-
gement [45].
MEC oval nuclei are filled with dispersed chro-
matin and clearly separated nucleoli. In perinuclear
cytoplasm there are clusters of cellular organelles,
cisterns of endoplasmic reticulum, numerous ribo-
somes, well-developed Golgi apparatus, multiple
vacuoles, and vesicles. Mitochondria are present in
both the perinuclear part of the cell and in process-
es (Fig. 3). These MEC features point toward their
activity in the synthesis of structural proteins of con-
tractile apparatus, components of basement lami-
na, and numerous regulatory and suppressor pro-
teins (Table 1).
MYOEPITHELIAL CELLS
DURING LACTATION
The basic physiological function of MECs during
lactation is milk ejection. Oxytocin triggers the con-
tractions of MECs located around the milk-storing
alveoli and excretory ducts, which leads to self-in-
duced milk expulsion.
Although the mechanisms of MECs and smooth
muscle cell contraction are very similar, their induc-
Figure 3. A higher magnification of mammary epithelium. Myo-
epithelial cell (MEC) is shown to be packed with microfilaments.
In perinuclear cytoplasm there are clusters of cellular organelles,
many ribosomes and multiple vacuoles. Plasma membrane forms
numerous invaginations — caveolae and subsurface vesicles
(arrows); EC — epithelial cells (¥14000).
tion is different. MEC contraction is stimulated by
oxytocin binding and activation of signalling path-
way mediated by Gaq-11 protein and phospholipase C.
The breakdown of phosphatidylinositol bisphos-
phate results in calcium concentration increase,
phosphorylation of myosin, and finally the contrac-
tion of the cell [50, 52]. Unlike in myocytes, the main
source of calcium ions in MECs is the extracellular
influx. In addition, intracellular compartments may
be engaged in the maintenance of the constant cal-
cium level during the contraction. In contrast to uter-
ine smooth muscles, oxytocin binding by MECs is
not accompanied by mitogen-activated protein kinase
(MAPK) activation nor by prostaglandin release [55].
As demonstrated in some experiments, oxytocin
availability is not the only prerequisite for MEC con-
traction, and the induction itself requires other, as
yet undefined factors, which might work in an auto/
/paracrine way. Oxytocin binding by MECs is accom-
panied by an increase in cytoplasmic cAMP concen-
tration; however, there is no evidence suggesting
the direct dependence between elevated cAMP and
myosin phosphorylation levels. These effects seem
to be mediated by different signalling pathways in-
cluding calcium increase, cAMP formation, and
MAPK activation [55].
Morphological observations of MEC contrac-
tion suggest that physiological concentrations of
oxytocin do not stimulate the contraction of all
MECs in lactating mammary glands but only the
cells surrounding the alveoli filled with milk. Milk
in particular secretory alveoli is produced in an
asynchronous way. If availability of oxytocin was
the only contraction inducer of MECs, then all of
them should contract independently of milk level,
which seems to be irrational from a physiological
point of view [43].
It is assumed that the modulator of MEC con-
traction, working in an auto/paracrine way, is par-
athormone related peptide (PTHrP), like in vascular
smooth muscle cells. PTHrP is synthesized in lumi-
nal cells and MECs of the lactating mammary gland,
and its receptors are present only in MECs. In vascu-
lar smooth muscle cells, the PTH/PTHrP 1 receptor,
like other vasodilators, activates the phosphatidyli-
nositol-Ca2+ signalling pathway. The presence of
PTH/PTHrP type I receptor, as demonstrated in our
own studies, in the Hs578Bst myoepithelial cell line
established from normal human breast tissue, as well
as the capability of PTHrP synthesis by these cells,
indicate the autocrine mechanisms of PTHrP action
[65]. Seitz et al. [60] suggests that the action of
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Table 1. Proteins and biomolecules specific for myoepithelial cells (MEC)
Molecule Function Diagnostic or clinical significance References
Structural proteins
Smooth muscle actin (SMA) Involved in MEC contraction. SMA expression is observed in 95% [10]
Identical as in smooth muscle of MECs of the normal mammary gland,
cells, myofibroblasts and and non-invasive cancers. No expression
pericytes is detected in invasive cancers.
Diagnosis of invasiveness should be
confirmed with a simultaneous expression
of SMA and collagen IV
Smooth muscle myosin The main component of MEC Similar to SMA, a useful marker in [14]
(heavy chains) — SMMHC contractile apparatus differentiation between invasive and
non-invasive breast cancers
Calponin Binds tropomyosin and F-actin. A useful marker differentiating MECs [14]
Participates in MEC contraction from spindle cells of the stroma, and
invasive from non-invasive cancers
H caldesmon (HCD) Cytoskeletal protein binding to actin Strong expression is specific for [42]
myoepithelial and smooth muscle
cells of small blood vessels
P-cadherin Is a Ca2+-dependent cell adhesive Expressed in MEC of the normal mammary [24]
molecule playing a key role in the gland, and occasionally in hyperplastic
maintenance of mammary gland tissues, and some non-invasive cancers
epithelium structure
Cytokeratins 5, 7, 14, 17 Specific components of MEC Enable identification of MECs in the [41, 78]
intermediate filaments normal mammary gland and breast
cancers, and differentiation of MEC
precursors during mammary gland
morphogenesis.
Desmoglein (Dsg3) and Dsg3 and Dsc3 desmosomal Responsible for the positioning of [57]
desmocollin (Dsc3) cadherins are specific for MEC MECs and maintenance of bilayer
desmosomes and hemidesmosomes structure of the mammary gland
epithelium
Non-structural molecules
Maspin Mammary gland specific serpin Tumour suppressor protein, the [54]
(serine proteases inhibitor) present expression of which decreases
exclusively in normal mammary gland with the level of malignancy.
MEC, and breast cancer epithelial cells Maspin inhibits tumour growth
and invasiveness inducing apoptosis
and inhibiting cell mobility and
angiogenesis
p63, p73 Nuclear proteins showing close Proteins responsible for the maintenance [5, 82]
homology to p53, p63, and p73 of progenitor cell populations in
expression in mammary gland mammary gland epithelium. Participate
is comprised to MEC nuclei in mammary gland morphogenesis
and the maintenance of the normal
structure of the gland
WT-1 (Wilms tumour 1) A transcription factor involved in WT-1 expression is constantly observed [19, 59]
gene expression, similarly as p53 in MECs, whereas in breast cancers it is
negatively correlated with tumour progression
S 100 Protein belonging to the big family S 100 protein is constitutively expressed [18, 27]
of proteins containing at least one in MECs and is often present in mammary
Ca2+ binding motif gland luminal cells. In breast cancers,
expression of S 100 protein is often
elevated and associated with tumour
progression and poor prognosis
Æ
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Table 1 (continued). Proteins and biomolecules specific for myoepithelial cells
Molecule Function Diagnostic or clinical significance References
CD10 (CALLA — common Metalloendopeptidase present on The enzyme exhibits stable expression [44]
acute lymphoblastic the surface of the cells responsible in normal mammary gland MECs. During
leukaemia antigen) for the inactivation of many biologically breast cancer growth and progression the
active peptides. Present on the lateral number of CD10 positive MECs undergoes
surface of MECs reduction, and the intensity of immuno-
cytochemical reaction decreases
CD44 The molecule secreted by MECs, Marker applied in breast cancer prognosis [2, 37]
inhibits cancer cells adhesion and
migration
CD 109 Participates in TGF-b signalling Present in mammary gland MECs, but not [26]
pathway inhibition expressed in secretory and ductal epithelial
cells. MEC marker applied in invasive cancer
breast diagnosis
14-3-3 sigma The product of cancer suppressor gene Expressed mainly in MECs of benign and [63]
transactivated by p53 in response to pre-invasive breast cancers. Applied in
DNA damage breast cancer prognosis
NRP-1 (neuropilin) A specific receptor for vascular MECs in hyperplastic and neoplastic [69]
endothelial growth factor in MECs tissues of the mammary gland exhibit higher
NRP-1 expression than normal tissue
PTHrP/PTHrPR (parathyroid PTHrP is produced both by myoepithelial PTHrP inhibits the growth and branching of [16, 81]
hormone-related protein/ and luminal cells, but in mammary excretory ducts during development. Exhibits
/parathyroid hormone-related glands only MECs exhibit its receptor proapoptotic and antiproliferative properties
protein receptor) in hyperplastic tissues of the mammary gland
PTHrP on MEC cells leads to their relaxation by stop-
ping the oxytocin triggered influx of calcium ions.
Another molecule that may be engaged in the
regulation of MEC contraction is nitric oxide (NO).
In mammary gland MEC, both in the resting and
lactation periods, the activity of nitric oxide synthase
(NOS-1), as well as the presence of NO receptor-
soluble guanylyl cyclase (sGC), were observed. sGC,
in an auto/paracrine way, catalyzes the conversion
of GTP to cGMP [79]. In smooth muscle cells, the
increase in cGMP concentration inhibits the influx
of calcium ions and thereby the activity of Ca2+-
-dependent myosin light chain kinase, which leads
to the relaxation of cells [46]. Because an identical
kinase is present in MEC, a similar mechanism of
auto/paracrine regulation of contraction may oper-
ate here.
An additional mechanism of the regulation of
MEC contraction is variable and diversified localiza-
tion of oxytocin receptors (OTR). The availability of
OTR may be regulated via their localization in spe-
cialized membrane microdomains such as lipid rafts
and caveolae, which may be connected with the
activation of different transduction pathways lead-
ing to a diversified response of MECs to oxytocin
signal [56].
THE ORIGIN AND DIFFERENTIATION
OF MYOEPITHELIAL CELLS
The mammary gland differentiates from ectoder-
mal epithelium, which, during the embryonic period,
forms the milk line. The epithelium of milk line invag-
inates into mesenchyma forming primary and later
secondary buds. These buds elongate and grow later-
al branches forming a complex system of ducts end-
ing with expanded terminal end buds (TEBs). The TEBs
undergo intensive growth and differentiation. A cap
cell layer surrounds the body cells constituting the cel-
lular material from which basal MEC and luminal cells
differentiate and are therefore thought to be multi-
potent stem cells (Fig. 4). Some of them remain undif-
ferentiated stem cells which settle in particular niches
of excretory ducts and secretory units [80].
Intensive development of the mammary gland
takes place during puberty, pregnancy (when the
process is stimulated by systemic hormones, oestro-
gens, progesterone, placental lactogens, and pro-
lactin), and after childbirth, when the combination
of systemic hormones, local growth factors, and milk
ejection evokes further development of the gland
structure [47].
MEC precursors are present on the entire length
of branched ducts of the mammary gland, and at
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Figure 4. The structure of terminal end buds (TEB) (A) and ductal and alveolar cells during pregnancy (B). A cap cell layer surrounds the body
cells. The cap cells can take on either a myoepithelial lineage or a luminal epithelial lineage and therefore are thought to be multipotent stem cells.
Differentiated myoepithelial and luminal epithelial cells line the neck of the TEB and the subtending duct. During midpregnancy the ducts are sur-
rounded by a basal layer of overlapping myoepithelial cells, whereas the alveoli cells are surrounded by a basket-like layer of myoepithelial cells.
Figure 5. Myoepithelial cells (MEC) surrounding breast excretory ducts highlighted by maspin immunoreactivity. MECs are arranged in
a continuous layer with their long axis being laid parallel to the ducts. Cross section (A), longitudinal section (B) (A and B ¥ 600).
Figure 6. Ductal carcinoma in situ (DCIS). The proliferating DCIS cells are localized within the large distended duct, which is still lined by
an intact layer of myoepithelial cells (MEC) exhibiting intense maspin immunoreactivity (arrows) (A ¥400; B ¥600).
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every stage of development. The analysis of mam-
mary gland ultrastructure demonstrated the pres-
ence of three types of epithelial cells: luminal cells,
myoepithelial cells, and basal pale cells, which, as
the authors suggest, may constitute the population
of stem cells. In human mammary glands, a gradual
transition of pale cells into fully differentiated MECs
was demonstrated, but there are no observations
of the transition of these cells into differentiated
luminal cells [64, 75].
Isolated suprabasal cells in three-dimensional
(3D) cultures in laminin-rich media form structures
similar to functional units of the mammary gland
(commonly referred to as terminal duct lobular units
[TDLUs]) with an internal layer of CK19 positive lu-
minal cells and an external layer of CK14 and a-SMA
positive cells similar to MECs. There is strong evi-
dence that luminal epithelial and myoepithelial cells
are derived from a suprabasal cell type [22].
The presence of cells with simultaneous CK19
and CK14 expression was observed in mammary
gland epithelium. These cells located within duct
bifurcations are relatively weakly differentiated and
dye-resistant. Planted into pure fat tissue they form
follicular and tubular structures, which proves that
they have full potential of differentiation [3]. The
analysis of human mammary gland specimens ex-
hibited a population of bipotential CK5 positive
cells differentiating either into luminal or myoepi-
thelial cells [9].
Recently, several populations of stem cells differ-
ing in determination level have been identified in
human mammary gland. A helpful combination of
markers, applied for the sorting of mammary gland
stem cells, is made up of EpCam (epithelial adhesion
molecules, also known as epithelial specific antigen
— ESA), CD49f, and MUC1 (luminal cells-specific gly-
coprotein). EpCam displays a strong expression in
luminal cells and poor expression in basal cells, and
the expression pattern for CD49f is reversed. Bipo-
tential basal stem cells, capable of differentiation into
luminal or myoepithelial cells, exhibit poor expres-
sion of EpCam, strong expression of CD49f, and no
expression of MUC1, whereas luminal progenitor cells
display strong expression of EpCam and the presence
of CD49f- and MUC1+  [17, 72].
In a suspension of cells freshly isolated from mam-
mary gland, 1% display the ability to proliferate and
form three types of colonies in the medium. Most of
them (70%) create tight clusters of cells displaying ex-
pression of CK18, CK19, and MUC1 antigens specific
for luminal cells, but no expression of CK14 typical for
basal cells. A further analysis showed the cells to present
luminal cell phenotype, high expression of EpCam, and
the presence of CD49f and MUC1 antigens. The second
population, in terms of quantity (25%), is formed by
bipotential progenitor cells with poor expression of
EpCam, strong expression of CD49f, and no expression
of MUC. These cells created colonies characterized by
the presence of cells with CK14–, K18+, K19+, and
MUC1 in their central area, and CK14+ basal cells in
the peripheral area. Both cell types, as demonstrated
using clonal analysis, descended from common progen-
itor cells. The third type of cells included stem cells of
MEC forming colonies consisting only of basal cells of
CK14+, CK18–, CK19–, and MUC1-phenotypes. Precur-
sors of MEC, as further analysis showed, originate di-
rectly from bipotential stem cells [71].
MYOEPITHELIAL CELLS IN
MORPHOGENESIS AND
ORGANIZATION OF MAMMARY
GLAND STRUCTURE
The location of MEC between the luminal cells
and the extracellular matrix suggests their active role
in the exchange of information between the extra-
cellular matrix and the luminal epithelium of the
gland, and therefore their participation in the regu-
lation of growth, morphogenesis, and the mainte-
nance of the proper two-layered structure of the
mammary gland (Fig. 5).
MECs show a strong expression of receptors of
integrins and growth factors such as EGF and FGF-2,
which may suggest their regulatory function. Activin,
belonging to the TGF-b superfamily, is expressed only
in MECs of mammary gland and plays a role in the
regulation of ducts growth [38]. Maspin, being ex-
clusively expressed in MECs, has been shown to play
a significant role in the morphogenesis, development,
and functioning of mammary gland. Maspin gene
overexpression coupled with WAP promoter (respon-
sible for the regulation of milk protein expression,
and active since half way through gestation until the
end of lactation) led to the inhibition of gland growth
and disturbances in the formation of mature gland
structures. Transgenic mice with maspin overexpres-
sion had a decreased number of alveolar structures
unable to synthesize milk components [83].
In normal mammary gland, only MECs display the
expression of OTR and are the hormone target [11].
Benson and Folley [8] were the first to demonstrate
the vital role of oxytocin in the regulation of differen-
tiation, growth, and involution of mammary gland.
Subsequent studies, performed on knocked-out mice
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unable to synthesize oxytocin, demonstrated their
inability to form the proper lobulo-alveolar structure
of mammary gland in the period of puberty, and the
impairment of the further development of the gland
during the postpartum period [77]. Oxytocin injec-
tion into non-lactating mice induces proliferation and
differentiation of MECs. This phenomenon was ob-
served only in the mice treated previously with proges-
terone and oestrogens. These findings suggest that
the proliferational effect of oxytocin depends on the
level of mammary gland development and works at
the hormonal stage corresponding to the pregnancy
period [58].
The expression of both oxytocin mRNA and pep-
tide observed in MEC primary cultures [12] suggests
that these cells may act as a local source of oxytocin
synthesis, and therefore may be involved in auto/
/paracrine regulation of proliferation and differenti-
ation of mammary gland cells at all stages of its
development.
The integrity of mammary gland epithelium is
maintained by a complex system of cell/cell and cell/
/extracellular matrix interactions mediated by cad-
herins and integrins.
In mammary gland P-cadherins are located only
in MECs and the cells of terminal end buds, while
E-cadherins are exclusively in luminal cells [15]. Virgin
mice with P-cadherin deficiency display accelerated
mammary gland growth, and luminal cells initiate
the synthesis of casein, likewise during the period
of early gestation. It finally leads to hyperplasia and
dysplasia of the gland epithelium. These observa-
tions indicate that P-cadherins mediate interactions
between myoepithelial and luminal cells and partici-
pate in the control over growth and differentiation
of mammary gland epithelium [53].
In epithelial cells, b-catenin is a component of
cadherin-containing intercellular junctions. The in-
teractions with MECs trigger the Wnt/b-catenin sig-
nalling pathway in luminal epithelium, the main
mediators of which are Tcf transcription factors. The
presence of both Tcf4 and Tcf1 was observed in
mammary gland epithelium; however, only in MECs
was the nuclear Tcf1 localization demonstrated [57].
A significant role in the formation of normal
mammary gland structure is played by desmosomal
cadherins: desmoglein (Dsg) and desmocollin (Dsc).
They display different expression in luminal and
myoepithelial cells. Dsg2 and Dsc2 are present in
both layers of the cells, while Dsg3 and Dsc3 occur
only in MECs. Co-culture of myoepithelial and lumi-
nal cells form bilayered structures resembling their
in vivo arrangement. The introduction of specific
peptides inhibiting myoepithelial Dsc3 and Dsg3 to
the co-culture causes distortions in the formation
of the proper bilayer epithelium structure and dis-
turbs the polarization of luminal cells [21]. These
observations prove that MECs play a significant role
in the arrangement of mammary gland structure and
polarization of luminal cells via direct interactions
between cells mediated by desmosomes [25].
Isolated mammary luminal cells in 3D cultures in
collagen I gel form lumenless alveolar structures.
Double labelling for MUC1/ESA and then for MUC1/
/occludin demonstrated that cells form clusters with
reversed polarity. Introducing MECs to the culture
caused the correct polarization of epithelial cells and
the forming alveolar structures to have clearly dis-
tinguished lumen.
In addition, the presence of laminin-1 (but not other
laminin isoforms; 5, 10, or 11) in the culture gel al-
lowed the formation of correct epithelium polariza-
tion. MECs are the only cells synthesizing laminin-1
(among other main components of the basement lam-
ina), and their introduction to the culture makes up
for laminin-1 deficiency, which leads to the appropria-
te formation of alveolar epithelial structures [22].
Although laminin-1 is the key regulator of cor-
rect polarization of epithelium and the morphogen-
esis of mammary gland, other molecules produced
by MECs may also take part in this process.
Except for the occurrence of all integrins present
in luminal cells, mammary gland MECs show an ex-
clusive strong expression of a1b1 and a5b5 integrins.
Inactivation of b1 integrin in virgin mice leads to
disturbances in the formation of ducts and their
branching, resulting in an improper arrangement of
the lobulo-alveolar structure of the mammary gland
during the gestation [20].
In MECs and cap cells in terminal end buds (TEB),
the presence of neogenin — the receptor of netrin-1
(which plays a significant role in the development
of the nervous system by directing neuronal pro-
cesses to their target locations) — has been de-
tected. The expression of netrin1 has also been ob-
served in internal cells of TEB and luminal cells. The
analysis of knockout mice devoid of neogenin or
netrin-1 expression show structural abnormalities
in TEB; cap cells separate from internal cells and the
basement lamina loses its integrity. Netrin-1/neoge-
nin interaction plays a significant role in the for-
mation of mammary gland cytoarchitecture both
via the regulation of cell adhesion and via some
unknown signalling pathways [68].
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MYOEPITHELIAL CELLS AS
SUPPRESSORS OF BREAST CANCER
MECs present in normal mammary glands and
benign forms of tumours are considered natural
suppressors of breast cancer. They inhibit the growth
of tumours and neoangiogenesis, induce apopto-
sis, and limit the mobility of cancer cells. MEC locali-
zation between the basement lamina and the layer
of luminal cells suggests their paracrine action on
adjacent luminal cells as well as on the connective
tissue and endothelial cells [48].
A commonly accepted hypothesis states that with
the increase in cancer malignancy the ratio of lumi-
nal to myoepithelial cells rises, while the invasive can-
cers are almost devoid of the latter. In invasive can-
cers, MEC markers — CK14, CK17, and vimentin —
are present in less than 20% of all tumours [76].
Although the presence of MECs is associated with
the maintenance of ductal cancer in situ (DCIS) in the
benign form even for a long period, some of these
cancers undergo malignant transformation. Compar-
ative analysis of gene expression has shown signifi-
cant differences between MECs accompanying DCIS
and MECs of normal mammary gland ducts. DCIS-as-
sociated MECs exhibit lowered expression of oxytocin
receptors, laminin-1, and thrombospondin, but high-
er expression of chemokines responsible for cellular
proliferation, migration, and invasiveness of cells such
as SDF1/CXCL12 and CXCL14. Moreover, an increase
in enzymes engaged in extracellular matrix degrada-
tion, such as numerous metalloproteinases, as well as
various epigenetic changes connected with higher levels
of DNA methylation, were observed in these cells [1].
These properties of DCIS-associated MECs may sug-
gest their paracrine effects on normal glandular epi-
thelium resulting in malignant transformation.
Myoepithelial cells associated with DCIS lose con-
tact with luminal cells, which leads to disturbances
in luminal cell polarization and inhibition of the base-
ment lamina component synthesis by MECs. In breast
cancers with laminin-1 synthesis deficiency in MECs,
even the presence of these cells was not correlated
with better prognosis [39]. On the other hand, breast
tumours with functioning MECs that synthesize base-
ment lamina components do not give distant me-
tastases and are correlated with better prognosis [32].
Therefore, it can be stated that the presence of MECs
in breast tumours inhibits the alterations associated
with malignant transformation [7].
A break of integrity of the MEC layer affects the
genetic and functional changes in the luminal cells
located above it. A decrease in expression of oestro-
genic receptors, higher frequency of heterozygosity
occurrence, higher cellular proliferation index, and
increase in expression of genes related to the active
mobility of cells and angiogenesis have been ob-
served in these cells.
Normal MEC and myoepithelial cell lines derived
from benign breast tumours produce relatively high
numbers of protease inhibitors and anti-angiogenic
factors [48]. HMS1 mammary myoepithelial cells (the
cell line derived from benign tumours) are charac-
terized by a high ratio of proteinase inhibitors to
proteinases, unlike mammary cancer cell lines where
the number of proteinases significantly prevail their
inhibitors. The analysis of the profile of inhibitors
secreted by MECs revealed the presence of tissue
proteases inhibitor (TIMP-1), plasminogen activator
inhibitor, and trypsin inhibitors such as a1-anti-
trypsin [70].
Numerous studies point towards a significant role
of fibroblasts in the progression and invasiveness of
cancers. The majority of metalloproteinases (MMP)
participating in cancer progression are fibroblasts
produced in response to signals coming from can-
cerous cells. MECs suppress the pro-invasive dialogue
between cancerous and fibroblast cells by the inhibi-
tion of MMP expression, the mechanism of which has
not been elucidated. There are some suggestions
pointing towards growth factors produced by MECs
(TGF-b, FGF-2, activin, or components of Wnt signal-
ling pathway) as the mediators reducing the expres-
sion of pro-invasive MMP in fibroblasts [30].
A break of integrity of the MEC layer and its at-
rophy in cancer tissue may be caused by an autoim-
munological reaction and the impact of leukocytes
and macrophages on the basement lamina, as well
as their direct action on MECs. An increase in leuko-
cytes and macrophage numbers is an evident fea-
ture of in-situ cancer transition into infiltrated inva-
sive forms, and it coincides with bad prognosis and
higher mortality rates. Leukocytes are able to force
the barrier of the basement lamina and the MEC
layer thanks to the secretion of numerous proteas-
es, effectively degrading their components [40].
In normal mammary gland as well as in vitro cul-
tures, MECs are able to synthesize and secret maspin.
Breast cancer cells co-cultured with MECs (HMS-1)
lose their capability of effective migration. A similar
effect was observed by culturing breast cancer cells
in medium previously used to culture MECs. The in-
troduction of dexamethasone into the co-culture of
MECs and breast cancer cells leads to a maspin syn-
thesis increase and completely inhibits the capabili-
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ty of cancer cell migration. Immunoprecipitation of
maspin in culture medium with specific anti-maspin
antibodies abolishes the suppression effect of the
medium on the invasiveness of cancerous cells [6].
In maspin-treated breast cancer cells, the profile
of integrin expression on the surface changes in direc-
tion promoting binding with collagen and fibronectin
(increased expression of a3 and a5 integrins accom-
panied by the decrease of others) [4]. Alterations
caused by maspin also include proteins which are en-
gaged in signalling pathways related to cell mobility
(reduced activity of Rac1 kinase and increased activity
of ERK1/2 and PI3K kinases) [49]. Another form of
maspin impact on cancer cell decreased mobility is the
inhibition of proteases engaged in plasminogen acti-
vation (responsible for the digestion of the extracellu-
lar matrix, which promotes the migration). The mecha-
nism of maspin action consists of binding urokinase
plasminogen activator (uPA), its precursor (pro-uPA),
and its receptor (uPAR) [62].
Moreover, MECs are able to cleave the surface
form of the CD44 molecule generating its soluble
form, which inhibits the migration ability of adja-
cent cancer cells [2].
MECs in normal mammary glands and in DCIS
tumours separate the luminal epithelium from the
blood vessels of the gland stroma, forming a barrier
that is impenetrable to the vessels (Fig. 6). Myoepi-
thelial cells (HMS) derived from benign mammary
gland tumours (myoepithelioma) are characterised
by high expression of active angiogenesis inhibitors
such as TIMP-1, thrombospondin, or maspin, and low
level of angiogenic factors. The comparison of xe-
nografts of breast cancer tumours derived from myo-
epithelial or luminal cells has shown an intensive
synthesis of extracellular matrix components and very
little neoangiogenesis in the first case, but almost
ten times higher neoangiogenesis in the second case.
Both HMS-1 myoepithelial cells and HMS-1 concen-
trated culture medium significantly inhibit migration
and proliferation of endothelial cells. This effect is
enhanced by phorbol esters but  stopped by cyclo-
heximide and dexamethasone [48]. Immunoprecipi-
tative analysis of the culture medium points to maspin
and thrombospondin as the key molecules responsi-
ble for angiogenesis inhibition by MECs [84].
Myoepithelial neoplasm-derived cells produced
in culture significantly lower quantities of vascular
endothelial growth factor and nitric oxide synthase
activity in response to hypoxia, when compared with
the cell line derived from luminal cancer [48]. This
observation supports the hypothesis assuming that
MECs, even those subjected to malignant transfor-
mation, exhibit natural anti-angiogenic capabilities.
An important function of MECs in cancer suppres-
sion is their involvement in steroid hormone metab-
olism. Comparative studies on the influence of 17-b
estradiol on steroid sulphatase (STS) in normal hu-
man MECs and breast cancer cells (MCF-7) have
shown STS activity to be more than a hundred times
higher in MECs [73]. Exposure to 17-b estradiol led
to a 70% reduction in STS activity in MCF-7 cells, and
a 9% activity increase in MECs, which suggests that
MECs may participate in the conversion of precur-
sors into active steroid hormones. The exposition of
MECs to tamoxifen enhances the synthesis of maspin
and inhibits maspin-dependent invasiveness of can-
cer cells. The introduction of 17-b estradiol inhibits
the effect of tamoxifen on MECs, which suggests that
the mechanism of tamoxifen action is dependent on
oestrogen receptors. Since MECs have ERb receptors
(but not ERa), it might be concluded that tamoxifen-
induced maspin secretion results from the triggering
of the signalling pathway initiated by ERb receptors,
and activation of transcription factors AP1 [61].
The presented data allow the notion suggesting
that MECs have a genetic program preventing not
only their own malignant transformation but also
the transition of noninvasive tumours derived from
luminal cells into malignant forms of breast cancer
in an autocrine or paracrine way.
However, the changes of the genetic expression
profile of MECs, which co-occur with the transfor-
mation of benign cancers into their malignant forms,
may modify MECs in such a way that allows them
to enforce proliferation, migration, and invasiveness
of cancerous cells [1].
BREAST CANCERS DERIVED FROM
MYOEPITHELIAL CELLS
The analysis of the genetic profile of breast can-
cers allows their subdivision into four basic histoge-
netic types: one normal breast tissue-like type, two
luminal-like types, one ERBB2-overexpressing type,
and one basal-like type. Each of the types is char-
acterized by a diverse clinical response [67]. The basal-
-like type of breast cancer derived from MECs com-
prises 2–18% of all invasive ductal breast cancers
and can be identified with the use of markers spe-
cific for MECs, such as cytokeratins (CK5, CK14,
CK17), smooth muscle cells actin and myosin, and
others, such as p63 or s100 protein [31].
Breast cancers of basal/myoepithelial type differ
from other ductal breast cancers in significant mor-
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phological features. They usually are high-grade (III)
tumours and often contain in their central area a non-
cellular substance consisting of necrotic cells debris,
collagen, and hyaline substance [74]. Besides the ex-
pression of MEC markers, these cancers are also char-
acterized by the lack of expression of progesterone
(PR), oestrogenes (ER), and HER-2 receptors [29]. The
microarray analysis of the immunophenotype and
genetic expression profile shows many similarities
between sporadic basal cancers and inherited can-
cers with BRCA1 mutation [35, 67]. Basal breast can-
cers, unlike luminal cancers, are characterized by
a high expression of gene coding for a2 and g2 laminin
chains and â4 integrin subunits [51].
Further analysis of mammary gland basal can-
cers has shown 82% frequency of TP53 mutation,
while in luminal-type cancers it was only 13%. TP53
mutations are associated with poor prognosis and
poor response to therapy [66]. Poor clinical progno-
sis is also related to the high cancer grade and the
lack of expression of steroid hormone receptors. In
rare cases, basal cancers are connected with in-
creased risk of brain metastases and higher mortal-
ity rates, independently of the lymph node status
and tumour size. Numerous clinical trials show that
breast cancers with 5 and 17 cytokeratins expres-
sion (specific for basal cells) exhibit poor prognosis
and shorter survival rates.
However, some authors argue that such an in-
terpretation is too simple because these might not
be pure myoepithelial cancers, and the presence of
MEC markers within the tumour may be caused by
luminal cells exhibiting high phenotypic plasticity,
or by stem cells with broad expression of both myo-
epithelial and luminal cell markers [13].
The basal type of breast cancer with poor clin-
ical prognosis, negative for oestrogen receptors,
has markers of both luminal and myoepithelial
cells, and MECs are partially differentiated, unlike
luminal cells which are highly unorganised. It
should be mentioned that MECs are highly resis-
tant to malignant transformation, and even if they
undergo the transformation the cancers derived
from MECs are benign, except for malignant myo-
epithelioma which is the least frequent form of
breast cancer [34].
SUMMARY AND CONCLUSIONS
Although myoepithelial cells of mammary gland
comprise the second population in the gland (with
respect to cell number), they have not been the sub-
ject of many scientific studies until recently when their
important role in the regulation of proliferation, dif-
ferentiation, and activity of luminal cells, and mor-
phogenesis of mammary gland have been observed.
The layer of MECs and basal lamina (most of the
components of which are produced by these cells)
form a selective barrier regulating bidirectional ex-
change of information between mammary epitheli-
um and stroma cells (fibroblasts, endothelial cells).
The regulation of luminal cell function and mam-
mary gland development may result from the direct
effect of the cells via integrins and cadherins of cell-
-cell junctions but may also be caused by the para-
crine influence on neighbouring cells through nu-
merous regulatory proteins.
MECs of normal mammary glands or benign
breast tumours are natural cancer suppressors, re-
sponsible for the maintenance of the proper struc-
ture of the gland.
In numerous studies, the inhibitory effect of MECs
on cancer growth, invasiveness, and angiogenesis
has been demonstrated. The elucidation of the mech-
anisms of MEC differentiation and their involvement
in mammary gland morphogenesis and malignant
transformation would allow better insight into
breast cancer biology resulting in the improvement
in cancer diagnosis and therapy.
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